Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

This publication has 26 references indexed in Scilit:

• Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot
  American Journal of Hematology, 2024
• Anti‐CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study
  American Journal of Hematology, 2024
• Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
  Blood Cancer Journal, 2024
• 2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
  American Journal of Hematology, 2023
• DESCAR-T, le registre national des patients traités par CAR-T Cells
  Bulletin du Cancer, 2021
• Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
  The Lancet Oncology, 2021
• Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials
  American Journal of Hematology, 2021
• CAR-T cell therapy: current limitations and potential strategies
  Blood Cancer Journal, 2021
• CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview
  Bone Marrow Transplantation, 2020
• ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
  Transplantation and Cellular Therapy, 2019